This oral preparation would offer a more convenient and comfortable option for patients, potentially leading to better treatment compliance.58,59 Overall, the future research direction of GLP-1RAs involves making them more similar to those in the human body, extending their duration of action, and creating oral formulations for easier administration.60,61 These advancements aim to improve patient experience, compliance, and treatment outcomes
Larsen, B
Cell Signal (2019) 63:109363
This made the sample representative of the study population (prefrail community dwelling Malaysian older adults)
Related products include: For customers browsing combination formats, Peptides Centre also offers CJC-1295 No DAC + Ipamorelin as a 10mg/10mg, or 20mg/20mg peptide blend
News-Medical, viewed 02 August 2026, Suggested Reading